On Wednesday, Acadia Healthcare Company Inc (NASDAQ:ACHC)’s shares inclined 4.05% to $66.27.
Acadia Healthcare Company, Inc. (ACHC) declared that it delivered a notice to redeem all of the Notes that remain outstanding following the consummation of the Tender Offer on November 2, 2015 (the “Redemption Date”). The Company will redeem the outstanding Notes on the Redemption Date in accordance with their terms.
Acadia Healthcare Company, Inc. develops and operates inpatient psychiatric facilities, residential treatment centers, group homes, and substance abuse facilities providing outpatient behavioral healthcare services to serve the behavioral health and recovery needs of communities in the United States, the United Kingdom, and Puerto Rico.
RiT Technologies Ltd. (NASDAQ:RITT)’s shares dropped -4.15% to $1.62.
RiT Technologies (RITT), a leading provider of Converged Infrastructure Administration Solutions that enable companies to maximize utilization and security of their network infrastructure declared recently its results for the second quarter and six months ended June 30, 2015.
Financial Highlights for the Second Quarter Ended June 30, 2015
- Revenue for Q2 2015 raised 172% to $4.5 million, contrast to $1.7 million in Q2 2014
- Gross margin for Q2 2015 improved to 47%, contrast to 31% in Q2 2014
- Net Income for Q2 2015 was $0.1 million, or $0.01 per (basic and diluted) share, contrast to a net loss of $(2.6) million or $(0.20) per (basic and diluted) share in Q2 2014
- Cash and cash equivalents as of June 30, 2015 was $1.2 million
- Shareholders’ equity as of June 30, 2015, raised to $5.2 million, contrast to $3.9 million on December 31, 2014
Financial Highlight for the Six Month Period Ended June 30, 2015
- Revenue for the first six months of 2015 raised 115% to $7.9 million, contrast to $3.7 million in the same period of 2014
- Gross margin for the first six months of 2015 improved to 46%, contrast to 36% in the same period of 2014
- Net profit for the first six months of 2015 was $0.1 million, or $0.01 per (basic and diluted) share, contrast to a net loss of $(4.5) million, or $(0.35) loss per (basic and diluted) share recorded in the first six months of 2014
RiT Technologies Ltd. provides intelligent infrastructure administration (IIM) and indoor optical wireless technology solutions worldwide. The company’s IIM products enhance security and network utilization for data centers, communication rooms, and work space environments.
At the end of Wednesday’s trade, CyrusOne Inc (NASDAQ:CONE)‘s shares surged 1.84% to $32.66.
CyrusOne declared that its Chief Financial Officer and Administrative Officer, Kimberly H. Sheehy, will be leaving the Company and will be succeeded by Gregory R. Andrews as Chief Financial Officer. Mr. Andrews will join the Company as an Executive Vice President on October 19, 2015, and will be designated as Chief Financial Officer following the filing of the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2015. In order to assist with the transition of financial reporting responsibilities for the Company, Ms. Sheehy will continue as an employee through December 31, 2015. Thereafter, Ms. Sheehy will serve as a consultant to the Company in connection with the preparation of the Company’s Annual Report on Form 10-K for the year ended December 31, 2015.
CyrusOne Inc., a real estate investment trust (REIT), owns, operates, and develops enterprise-class, carrier-neutral, and multi-tenant data center properties. The company provides mission-critical data center facilities that protect and ensure the continued operation of information technology infrastructure.
United Therapeutics Corporation (NASDAQ:UTHR), ended its Wednesday’s trading session with -4.18% loss, and closed at $131.24.
United Therapeutics Corporation (UTHR) declared that it has reached a Settlement Agreement with Sandoz Inc. (“Sandoz”) regarding ongoing litigation concerning certain patents regarding United Therapeutics’ product, Remodulin® (treprostinil) Injection, and Sandoz’s Abbreviated New Drug Application (“ANDA”) seeking approval by the U.S. Food and Drug Administration to market a generic version of Remodulin.
Under the Settlement Agreement, United Therapeutics granted to Sandoz a non-exclusive license to manufacture and commercialize the generic version of Remodulin described in its ANDA filing in the United States startning on June 26, 2018, although Sandoz may be permitted to enter the market earlier under certain circumstances. The license comprised of in the Settlement Agreement does not permit Sandoz the right to manufacture a generic version of any other United Therapeutics product, such as Tyvaso® (treprostinil) Inhalation Solution or Orenitram® (treprostinil) Extended-Release Tablets, nor does it grant any rights with respect to any technology associated with the Remodulin Implantable System being developed by the Company and Medtronic Inc., or the pre-filled semi-disposable pump system being developed by the Company and DEKA Research & Development Corp. The Settlement Agreement does not grant Sandoz any rights other than those required to launch Sandoz’s generic version of Remodulin.
United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening conditions worldwide. Its lead product comprises Remodulin, an injection used for the treatment of pulmonary arterial hypertension (PAH).
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
